As at May 8, 2025, the CORT stock has a price-to-earnings ratio of 56.2. This is based on the current EPS of $1.27 and the stock price of $71.38 per share. An increase of 20% has been recorded in the PE ratio compared to the average of 47.0 of the past four quarters.
The mean historical PE ratio of Corcept Therapeutics over the last nine years is 48.78. The current 56.2 price-to-earnings ratio is 15% more than the historical average. In the past nine years, CORT's PE ratio reached its highest point in the Jun 2016 quarter at 546, with a price of $5.46 and an EPS of $0.01. The Sep 2018 quarter saw the lowest point at 10.54, with a price of $14.02 and an EPS of $1.33.
Maximum annual increase: 92.62% in 2020
Maximum annual decrease: -84.73% in 2017
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 37.33 | 17.24% | $50.39 | $1.35 |
2023 | 31.84 | 48.92% | $32.48 | $1.02 |
2022 | 21.38 | 4.75% | $20.31 | $0.95 |
2021 | 20.41 | -28.21% | $19.8 | $0.97 |
2020 | 28.43 | 92.62% | $26.16 | $0.92 |
2019 | 14.76 | -28.18% | $12.1 | $0.82 |
2018 | 20.55 | 29.73% | $13.36 | $0.65 |
2017 | 15.84 | -84.73% | $18.06 | $1.14 |
2016 | 103.71 | N/A | $7.26 | $0.07 |
2015 | N/A | N/A | $4.98 | -$0.06 |
2014 | N/A | N/A | $3 | -$0.31 |
2013 | N/A | N/A | $3.21 | -$0.46 |
2012 | N/A | N/A | $1.43 | -$0.41 |
2011 | N/A | N/A | $3.42 | -$0.39 |
2010 | N/A | N/A | $3.86 | -$0.38 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Mar 2025 | 89.94 | 140.93% | $114.22 | $1.27 |
Dec 2024 | 37.33 | 9.7% | $50.39 | $1.35 |
Sep 2024 | 34.03 | 27.79% | $46.28 | $1.36 |
Jun 2024 | 26.63 | 21.6% | $32.49 | $1.22 |
Mar 2024 | 21.9 | -31.22% | $25.19 | $1.15 |
Dec 2023 | 31.84 | 2.84% | $32.48 | $1.02 |
Sep 2023 | 30.96 | 23.84% | $27.25 | $0.88 |
Jun 2023 | 25 | 1.58% | $22.25 | $0.89 |
Mar 2023 | 24.61 | 15.11% | $21.66 | $0.88 |
Dec 2022 | 21.38 | -9.94% | $20.31 | $0.95 |
Sep 2022 | 23.74 | 1.84% | $25.64 | $1.08 |
Jun 2022 | 23.31 | 2.46% | $23.78 | $1.02 |
Mar 2022 | 22.75 | 11.46% | $22.52 | $0.99 |
Dec 2021 | 20.41 | -5.64% | $19.8 | $0.97 |
Sep 2021 | 21.63 | -17.41% | $19.68 | $0.91 |
The current PE ratio of CORT is above its 3, 5 and 10-year historical averages.
When compared to its peer LLY, CORT's PE ratio is lower, but it is higher than JNJ's and NVS's. Corcept Therapeutics's PE ratio is trading above the peer group average of 26.07.
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 11.27 | $194.98B |
PFE Pfizer Inc | 16.53 | $130.59B |
NVS Novartis AG | 17.1 | $215.78B |
JNJ Johnson & Johnson | 17.18 | $374.53B |
BMY Bristol Myers Squibb Co | 17.49 | $95.4B |
BMRN Biomarin Pharmaceutical Inc | 21.75 | $11.47B |
MNKD Mannkind Corp | 46.3 | $1.41B |
CORT Corcept Therapeutics Inc | 56.2 | $7.57B |
LLY ELI LILLY & Co | 60.9 | $712.18B |
ESPR Esperion Therapeutics Inc | N/A | $176.64M |
The price to earnings ratio for CORT stock is 56.2 as of May 8, 2025.
Over the last 3 years, the average PE ratio for CORT stock is 32.56.
Over the last 5 years, the average PE ratio for CORT stock is 28.65.
In the last nine years, the Jun 2016 quarter recorded the highest quarterly PE ratio at 546.
CORT's current price to earnings ratio is 15% above its 9-year historical average.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (May 8, 2025), Corcept Therapeutics's stock price is $71.38. The earnings per share for the trailing twelve months (TTM) ending Mar 2025 is $1.27. Therefore, Corcept Therapeutics's price to earnings ratio for today is 56.2. PE RATIO(56.2) = STOCK PRICE($71.38) / TTM EPS($1.27)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.